Skip to content

Remote Ischemic Conditioning to Attenuate Myocardial Death and Improve Operative Outcome.

Effect of Remote Ischemic Conditioning on Ischemia and Reperfusion Injury in Patients Submitted to Coronary Artery Bypass Grafting.

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03363958
Acronym
RICARDO
Enrollment
80
Registered
2017-12-06
Start date
2014-01-01
Completion date
2020-01-01
Last updated
2017-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Bypass, Ischemic Postconditioning, Ischemic Preconditioning, Myocardial, Myocardial Reperfusion Injur

Keywords

myocardial protection, remote ischemic preconditioning, remote ischemic postconditioning, cardiac surgery

Brief summary

This study evaluates the addition of remote ischemic preconditioning and postconditioning to standard myocardial protection protocol in patients submitted to off - pump coronary artery bypass grafting in a prospective, 1:1 randomized, double blind fashion. An interventional group will receive remote ischemic preconditioning 24-hours before OP-CABG, immediately before surgery and within 60 minutes following surgery by means of lower limb ischemia achieved by pressure cuff inflation, whereas control group will receive sham procedure perioperatively.

Detailed description

In a prospective, 1:1 randomized and double blind fashion, the study will evaluate the impact of remote ischemic preconditioning, both immediate and second window of protection (24 hours and immediately before surgery) with remote ischemic postconditiong on operative outcomes in patients submitted to coronary artery bypass grafting without use of extracorporeal circulation. Remote ischemic conditioning was found to provide protection against necrosis and apoptosis due to ischemia and reperfusion injury, a phenomenon observed during coronary artery bypass grafting. That in turn was associated with poor postoperative outcomes, predominantly poor survival. Remote ischemic preconditioning will be provided by repeated lower leg ischemia and reperfusion with pressure cuff inflation for five minutes and deflation for five minutes in three consecutive cycles. Remote ischemic preconditioning will be performed 24 hours before CABG and immediately before surgery. Remote ischemic postconditioning will be performed within 60 minutes following the last coronary artery bypass graft completion and the restoration of coronary blood flow. The study will assess clinical endpoints such as postoperative acute myocardial infarction (type 5 MI), postoperative mortality, postoperative renal failure and laboratory outcomes such as postoperative serial measurements of troponin T release or glomerular filtration rate as secondary outcomes.

Interventions

PROCEDURERemote Ischemic Preconditioning with Postconditioning

Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.

PROCEDURESham RIPC procedure

Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.

Sponsors

Medinet Heart Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Patients qualified to coronary artery bypass grafting according to ESC/EACTS Guidelines of myocardial revascularization, suffering from: * Multivessel coronary artery disease amenable for surgical treatment * Negative history of previous cardiac or vascular surgery in childhood and afterwards. * Negative history of active neoplastic disease, neither past medical history of oncological treatment * Patients with non insulin dependent diabetes mellitus treated chronically with oral derivatives of sulfonylourea such as but not limited to: glibenclamide.

Exclusion criteria

Patients suffering from acute insuficiency of any organ/ system and those suffering from end stage organ failure such as: * Chronic renal disease - KDOQI stage ≥ 3; * Chronic renal failure class A by Child - Pugh'a; * Chronic respiratory failure (type I and II according to Campbell et al. and type I according to Wood et al.); * Chronic intermittent claudication class 2A according to Fontaine;

Design outcomes

Primary

MeasureTime frameDescription
Postoperative myocardial necrosis72 hours postoperativelySerial mesurements of High - Sensitive Troponin T release
Postoperative kidney injury7 days postoperativelySerial measurements of estimated glomerular filtration rate by creatinine

Secondary

MeasureTime frameDescription
Perioperative mortality30 days postoperatively30-day all cause mortality
Perioperative myocardial infarction30 days postoperatively30-day myocardial infarction
Postoperative Acute Kidney Injury30 daysPrevalence of acute kidney injury according to Society of Thoracic Surgeons definitions of outcomes.

Countries

Poland

Contacts

Primary ContactJakub S. Marczak, M.D.
marczak@space.pl0048883774566
Backup ContactSleiman S. Aboul - Hassan, M.D.
s.aboulhassan@gmail.com0048683882194

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026